Search Result

All Related Services Other Content

API Crystallization
Crystal Pharmatech and the Future of Pharma at AAPS PharmSci 360 After a 3-year hiatus, the AAPS 2022 PharmSci 360 will mark the in-person return of one of the largest and most influential pharmaceutical industry conferences of the year. At the Boston Convention an...
Unveil Key Factors Influencing the Physical Stability of Amorphous Solid Dispersions In recent years, the utilization of Amorphous Solid Dispersions (ASD) has gained increasing interest, particularly for enhancing the solubility of drugs with inherently low solubility. Within ASDs, dr...
Co-crystals
Crystal Pharmatech Raring to Go to ChemOutsourcing 2022 Crystal Pharmatech is set to join ChemOutsourcing 2022, the most extensive USA-based API and pharmaceutical ingredients show. From September 7-9 at the Hilton Hotel, Parsippany, New Jersey, Crystal Ph...
Characterization and Evaluation of Amorphous Solid Dispersion (ASD) - Part 1 In previous articles, we have explored prevalent techniques for producing Amorphous Solid Dispersion (ASD), such as spray drying and hot melt extrusion, highlighting their respective benefits, limitat...
CPHI North america - Meet Us at Booth #530 Crystal Pharmatech is now more than just your API Form and Solid-State Research Partner. In addition, we can also be your Formulation Development and Innovative Technology Partner. Collectively, Cryst...
Impact of Solid-state in Early Development
Optimizing Polymer Selection for Amorphous Solid Dispersion in Hot Melt Extrusion Processes Hot melt extrusion (HME) technology is widely used in the development of amorphous solid dispersions, offering advantages such as a solvent-free preparation process, continuous operation, high automat...
Optimal Preclinical Formulation Development
Salts
Meet Crystal Pharmatech at AAPS National Biotechnology Conference Crystal Bio's CSO, Billy Wu, Ph.D. will be in San Francisco with Crystal Pharmatech's BD Director, Chris Heard, for the American Association of Pharmaceutical Scientists (AAPS) | @aapscomms Na...
Crystal's Perspective: Polymorph Patent Landscape of 28 FDA-Approved Small Molecule Drugs in 2024 Crystal’s Perspective: Polymorph Patent Landscape of 28 FDA-Approved Small Molecule Drugs in 2024 In 2024, the U.S. Food and Drug Administration (FDA) approved a total of 50 new drugs [1], including ...
Pharmaceutical Solid-state Forms
How to Mitigate Disproportionation of API Salts in Pharmaceutical Formulations Salt formation is a well-established strategy for improving the physicochemical properties of active pharmaceutical ingredients (APIs) containing ionizable groups. This approach is particularly effect...